Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
about
Circulating tumor cells: approaches to isolation and characterizationMinimal residual disease in breast cancer: an overview of circulating and disseminated tumour cellsThe promise of circulating tumor cell analysis in cancer managementCirculating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer researchHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerAssay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathwaysNanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancerTowards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis.Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment.Analysis of circulating tumor cells in breast cancer.Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.An integrated microfluidic chip system for single-cell secretion profiling of rare circulating tumor cells.Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin.Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.Akt2 kinase suppresses glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-mediated apoptosis in ovarian cancer cells via phosphorylating GAPDH at threonine 237 and decreasing its nuclear translocationEfficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.Clinical relevance and biology of circulating tumor cells.Circulating tumor cells measurements in hepatocellular carcinoma.Role of ErbB Receptors in Cancer Cell Migration and InvasionAntibody-nanoparticle conjugates to enhance the sensitivity of ELISA-based detection methodsExpression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cellspERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.Multiparameter Evaluation of the Heterogeneity of Circulating Tumor Cells Using Integrated RNA In Situ Hybridization and Immunocytochemical Analysis.Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells.Recent advances in the molecular characterization of circulating tumor cells.Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancerCirculating cancer cells.Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance.Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy.Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment.Plasticity of disseminating cancer cells in patients with epithelial malignancies.Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies.Circulating tumor cells, enumeration and beyond.
P2860
Q24631347-E4301E7E-0F4B-4E52-8C47-FA2DB24C7B2BQ26748850-0CB892C6-62AA-44C0-905A-5E13895830C0Q27022113-88DD14F9-3558-45C3-805F-0DD36F37DE29Q27024191-45D2862B-FF59-4D5D-BE27-C026A5BCD90CQ27025863-51EA75C1-6B61-4EA4-9C55-62C30D65D629Q28397338-6D440157-4830-40C7-B433-B72DEFAC0397Q28480835-F4604DC4-A2F7-41BA-A823-31AB603C0CE8Q30445250-56E9917D-0442-4103-BEAD-1727AD747B4CQ30887474-FEB76E7A-7BC5-45CC-8360-85C26129FE48Q31006508-54EF3093-7B46-437C-A27B-AE38D841EEBDQ33674656-F70135C3-AA0E-41E4-8D65-D19ADA124CBFQ33705431-BF4ECD68-7CA6-49EB-93E1-A5B36E39BA01Q34156275-CF1C84B7-FA7B-44D0-91C4-E1B2D723AC08Q34231456-4BBC913F-C395-4942-80B4-687383EFE198Q34706426-45DEA738-60F9-4365-97CB-72386F6E416BQ35000713-FF909523-E0E1-4B8E-A89E-B1B0ADFFDDC6Q35157131-17927591-C1A9-40F5-8254-529EE1E579BCQ35558093-68E3EF5F-C700-45BA-A694-5B9769DEACECQ35604944-A9300E7D-42E1-4437-B4C6-94170C959B25Q35665814-F82F587C-9C61-4D22-8994-B34885B0E8C5Q35749122-C511B87B-D818-44EE-B12D-2EC33974AE28Q35889548-FF975629-8CB7-4B43-923A-E3418C3089E1Q36011412-52735CBB-652D-4EFA-AF87-F846C467C3E3Q36311027-7A24F654-A219-4E70-A2DD-ECE46818ED12Q36369268-CDF66702-2304-4BD4-BA07-8343BEC11F7FQ36393149-5F561E1A-F0C6-4AB2-86C0-10B8D3B1307DQ36771900-2D56144C-DB81-478D-80D7-EA68D9E75293Q37360176-3DC4F439-4034-400D-9A0D-C3CE4DACF1EEQ37398787-E34120A2-F0FE-4DEB-AF1C-167726A2ADE1Q37405531-DD9AA53A-EE06-4F5B-8F73-81E9C9A3E9FDQ37693504-04D78CE9-7D67-4E73-98B6-7A1FC14E8352Q37706346-37F75ECB-1781-42AD-ABFD-EC4C47ABCD85Q37719099-D48DCAD9-CAAE-4EE5-889F-91AAE90738C5Q37799957-0ED7BBDA-6E23-4B7F-B175-04D3E010E4A4Q37890969-CB988D2C-AA88-45E2-B31B-BF6930EFFF8AQ37898107-1B8BF33A-B8FE-4973-9C60-CFE8B3653684Q38018253-955EB581-A617-46A1-9712-D3EB552B0AF8Q38021683-514E31A0-BECD-498D-9FE8-4EF038E8E5F5Q38097525-67200783-6A81-4A2D-8FE7-AD64AD8749ADQ38166574-5F766776-6F75-480E-8D81-F738D9B696A3
P2860
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phosphorylated EGFR and PI3K/A ...... ells of breast cancer patients
@en
Phosphorylated EGFR and PI3K/A ...... lls of breast cancer patients.
@nl
type
label
Phosphorylated EGFR and PI3K/A ...... ells of breast cancer patients
@en
Phosphorylated EGFR and PI3K/A ...... lls of breast cancer patients.
@nl
prefLabel
Phosphorylated EGFR and PI3K/A ...... ells of breast cancer patients
@en
Phosphorylated EGFR and PI3K/A ...... lls of breast cancer patients.
@nl
P2093
P2860
P356
P1476
Phosphorylated EGFR and PI3K/A ...... ells of breast cancer patients
@en
P2093
Antonia Kalykaki
Christos Stournaras
Dimitris Mavroudis
Galatea Kallergi
Sofia Agelaki
Vassilis Georgoulias
P2860
P2888
P356
10.1186/BCR2149
P577
2008-09-29T00:00:00Z
P5875
P6179
1011875653